Article: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
AuthorsPan, CQ6
Tong, M9
Kowdley, KV10
Hu, K3
Chang, T8
Lai, C7
Yoon, SK1
Lee, SS2
Cohen, D5
Tang, H5
Tsai, N4
KeywordsAntiviral Therapy
Hepatitis B Virus
Nucleos(T)Ide Analogue
Issue Date2012
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
CitationClinical Gastroenterology And Hepatology, 2012 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.cgh.2012.03.016
AbstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
ISSN1542-3565
2011 Impact Factor: 5.627
2011 SCImago Journal Rankings: 0.389
DOIhttp://dx.doi.org/10.1016/j.cgh.2012.03.016
DC Field
Value
dc.contributor.authorPan, CQ
dc.contributor.authorTong, M
dc.contributor.authorKowdley, KV
dc.contributor.authorHu, K
dc.contributor.authorChang, T
dc.contributor.authorLai, C
dc.contributor.authorYoon, SK
dc.contributor.authorLee, SS
dc.contributor.authorCohen, D
dc.contributor.authorTang, H
dc.contributor.authorTsai, N
dc.date.accessioned2012-09-05T05:32:07Z
dc.date.available2012-09-05T05:32:07Z
dc.date.issued2012
dc.description.abstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationClinical Gastroenterology And Hepatology, 2012 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.cgh.2012.03.016
dc.identifier.doihttp://dx.doi.org/10.1016/j.cgh.2012.03.016
dc.identifier.hkuros208887
dc.identifier.issn1542-3565
2011 Impact Factor: 5.627
2011 SCImago Journal Rankings: 0.389
dc.identifier.scopuseid_2-s2.0-84865319280
dc.identifier.urihttp://hdl.handle.net/10722/163490
dc.languageeng
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
dc.publisher.placeUnited States
dc.relation.ispartofClinical Gastroenterology and Hepatology
dc.subjectAntiviral Therapy
dc.subjectHepatitis B Virus
dc.subjectNucleos(T)Ide Analogue
dc.titleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
dc.typeArticle
Author Affiliations
  1. The Catholic University of Korea
  2. University of Calgary
  3. UCI Medical Center
  4. University of Hawaii at Manoa
  5. Bristol-Myers Squibb
  6. Mount Sinai School of Medicine
  7. Queen Mary Hospital Hong Kong
  8. National Cheng Kung University
  9. University of California, Los Angeles
  10. Virginia Mason Medical Center